For more than a year, the biopharma industry has had to swiftly react to various tariff threats from the Trump administration. | The president has rolled out a 100% tariff rate on patented ...

The U.S. will impose a 100% tariff on drug imports with some exceptions. Takeda plans to cut 634 jobs in the U.S. as part of ...

Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...

After a wave of high-profile pledges to bring pharmaceutical manufacturing back to the United States, a clearer picture of ...

The U.K. can officially declare itself free of tariffs on drug exports to the U.S. after its government signed off on the ...

With conflict in the Middle East bringing on a global energy market squeeze, one major pharma supplier is raising prices ...

With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of ...

A year after revealing his “Liberation Day” trade policy initiatives, U.S. President Donald Trump is set to announce tariffs ...

As senior director of client services for The Trade Desk, Elizabeth Keenan oversees teams responsible for audience strategy, ...

Pfizer has emerged victorious in a legal brawl with Poland and Romania over contested COVID vaccine orders, with a Belgian ...

Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...

Iterum took its time launching Orlynvah, debuting the drug in August 2025, almost a full year after securing approval. That ...